急速成長的印度學名藥市場 是由出版商RNCOS E-Services Pvt. Ltd.在2011年08月所出版的。
這份英文市場調查報告書包含60 Pages 價格從美金1000起跳。
受到非洲的抗HIV藥等全球整體成本效率性醫藥品需求的擴大，印度學名藥醫藥品產業持續穩定成長。一般預測2011∼2013年該產業的成長率約為年平均17%。
本報告提供印度的學名藥(非專利處方藥)市場相關分析，整體市場結構和最新的市場趨勢，全球性市場機會，主要的推動及阻礙市場要素，法規環境，再加上主要企業簡介等資訊彙整，為您概述為以下內容。
第1章 分析師的見解
第2章 分析方法
第3章 印度的學名藥市場:概況
第4章 主要市場推動因素
- 出口的增加
- 民間投資
- 專利失效
- 學名藥品接受度的增加
第5章 產業的實際成果
第6章 印度的學名藥企業市場機會
第7章 新的市場趨勢
第8章 法規環境
第9章 產業的阻礙因素與建議
第10章 競爭環境
- 產業結構
- 主要企業
- Ranbaxy
- Cipla Ltd.
- Jubilant
- Sun Pharmaceuticals
- Zydus Cadila
- Dr. Reddy's Laboratories
- Lupin Ltd.
- Aurobindo Pharma
- Glenmark Pharma
- Piramal Healthcare
圖表一覽
Abstract
The world has witnessed a sharp increase in the demand for cost-effective
generic drugs in a decade. In such a scenario, India's rise as a generic
destination is the blessing for people in under developed countries or
patients looking for cheap medicines. Strong supply of anti retroviral drugs
to African countries by Indian drug manufacturers is a case in point. The
after-impact of economic slowdown did not influence the Indian generics
sector, and the growth phenomenon continued to remain stable. In future also,
factors like patent expiries, investment, and private sector participation
will boost the sector and it is estimated that generic drugs market will grow
at a CAGR of around 17% between FY 2011 and FY 2013.
Our team of research has found that regions like US, Europe, Japan, and Africa
offer immense opportunities to Indian drug manufacturers who already hold a
10.5% share in the US generics market in 2010. Countries in the European and
African regions are also the prime consumers for Indian generics medicines.
Moreover, an increasing number of FDA, WHO approved plants and agreements
between big pharma and domestic generic players all indicate towards improved
perception of India as a generics hub.
The Indian generics drug market is surrounded by some key developments that
offer huge opportunities as well as threat. Increasing influence of foreign
multinationals has become a cause of concern for authorities and market
players. At the same time, patent expiries may turn out to be a growth
booster. Government support, in such a case, can become an important factor.
There are some key trends that have been impacting market development and the
report has analyzed them in a prudent manner.
The report, " Booming Generics Drug Market in India" provides an insight into
the generics drug market in India and analyzes growth in the sector revenue.
It addresses several issues that are of concern and come up with probable
solution. The report provides forecast for key areas and uses proper methods
and base for the same. The regulatory environment has also been discussed so
that clients may acquaint themselves with the government role in the Indian
generics sector. Last but not the least, the description, key developments,
and strength-weakness analysis of the active market players add value to the
overall analysis.
Table of Contents
1. Analyst View
2. Research Methodology
3. Indian Generics Market - An Overview
4. Key Market Drivers
- 4.1 Increasing Export
- 4.2 Private Investments
- 4.3 Patent Expiries
- 4.4 Increasing Acceptance of Generics
5. Industry Performance
- 5.1 Market Size and Growth
- 5.2 Branded and Generics
6. Opportunities for Indian Generics Companies
- 6.1 US
- 6.2 Europe
- 6.3 Japan
- 6.4 Africa
7. Emerging Industry Trends
8. Regulatory Environment
9. Industry Restraints and Recommendations
- 9.1 Counterfeit Drugs
- 9.2 Lack of Promotional Initiatives
- 9.3 Quality Issues
10. Competitive Landscape
- 10.1 Industry Structure
- 10.2 Key Players
- 10.2.1 Ranbaxy
- 10.2.2 Cipla Ltd.
- 10.2.3 Jubilant
- 10.2.4 Sun Pharmaceuticals
- 10.2.5 Zydus Cadila
- 10.2.6 Dr. Reddy's Laboratories
- 10.2.7 Lupin Ltd.
- 10.2.8 Aurobindo Pharma
- 10.2.9 Glenmark Pharma
- 10.2.10 Piramal Healthcare
List of Figures:
- Figure 4-1: Drugs and Pharmaceutical Export (Billion INR), FY 2005 to FY
2010
- Figure 5-1: Pharmaceutical Market (Billion INR), FY 2009 to FY 2013
- Figure 5-2: Generics Market (Billion INR), FY 2009 to FY 2013
- Figure 5-3: Share of Generics in Pharmaceutical Market (FY 2010)
- Figure 6-1: Global - Forecast for Generics Market by Region (%), 2013
- Figure 6-2: Market Share of Indian Companies in US Generics Sector
(2008-2010)
- Figure 6-3: US - Patent Expiries (Billion US$), 2011-2015
List of Tables:
- Table 4-1: Blockbuster Drugs Going Off-patent Globally (2011-2015)
- Table 7-1: Key M&A in the Generics Market
- Table 10-1: Ranbaxy - Strengths and Weaknesses
- Table 10-2: Cipla Ltd. - Strengths and Weaknesses
- Table 10-3: Jubilant - Strengths and Weaknesses
- Table 10-4: Sun Pharmaceuticals - Strengths and Weaknesses
- Table 10-5: Zydus Cadila - Strengths and Weaknesses
- Table 10-6: Dr. Reddy's Laboratories - Strengths and Weaknesses
- Table 10-7: Lupin Ltd. - Strengths and Weaknesses
- Table 10-8: Aurobindo Pharma - Strengths and Weaknesses
- Table 10-9: Glenmark Pharma - Strengths and Weaknesses
- Table 10-10: Piramal Healthcare - Strengths and Weaknesses
